The Journal of Experimental Medicine
Keystone Symposia
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents
Published online June 11, 2007
doi:10.1084/jem.20061845
The Journal of Experimental Medicine, Vol. 204, No. 7, 1559-1569
The Rockefeller University Press, 0022-1007 $30.00
© 2007 Roberts et al.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow PPT slides of all figures
Right arrow Supplemental Material Index
Right arrow Alert me when this article is cited
Right arrow Citation Map
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new content in the JEM
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Roberts, Z. J.
Right arrow Articles by Vogel, S. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Roberts, Z. J.
Right arrow Articles by Vogel, S. N.
Related Collections
Right arrowRelated Article
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

ARTICLE

 The chemotherapeutic agent DMXAA potently and specifically activates the TBK1–IRF-3 signaling axis

Zachary J. Roberts1, Nadege Goutagny2, Pin-Yu Perera3, Hiroki Kato4, Himanshu Kumar4, Taro Kawai4, Shizuo Akira4, Ram Savan5, David van Echo5, Katherine A. Fitzgerald2, Howard A. Young5, Lai-Ming Ching6, and Stefanie N. Vogel1

1 Department of Microbiology and Immunology, University of Maryland, Baltimore, Baltimore, MD 21201
2 Division of Infectious Diseases, University of Massachusetts Medical School, Worcester, MA 01605
3 Veterans Administration Medical Center, Washington, DC 20422
4 Department of Host Defense, Research Institute for Microbial Diseases, Osaka University, Osaka 565-0871, Japan
5 Laboratory of Experimental Immunology, National Cancer Institute-Frederick, Frederick, MD 21702
6 Auckland Cancer Society Research Centre, Faculty of Medical and Health Sciences, University of Auckland, Auckland 1000, New Zealand

CORRESPONDENCE Stefanie Vogel: svogel{at}som.umaryland.edu

Vascular disrupting agents (VDAs) represent a novel approach to the treatment of cancer, resulting in the collapse of tumor vasculature and tumor death. 5,6-dimethylxanthenone-4-acetic acid (DMXAA) is a VDA currently in advanced phase II clinical trials, yet its precise mechanism of action is unknown despite extensive preclinical and clinical investigations. Our data demonstrate that DMXAA is a novel and specific activator of the TANK-binding kinase 1 (TBK1)–interferon (IFN) regulatory factor 3 (IRF-3) signaling pathway. DMXAA treatment of primary mouse macrophages resulted in robust IRF-3 activation and ~750-fold increase in IFN-ß mRNA, and in contrast to the potent Toll-like receptor 4 (TLR4) agonist lipopolysaccharide (LPS), signaling was independent of mitogen-activated protein kinase (MAPK) activation and elicited minimal nuclear factor {kappa}B–dependent gene expression. DMXAA-induced signaling was critically dependent on the IRF-3 kinase, TBK1, and IRF-3 but was myeloid differentiation factor 88–, Toll–interleukin 1 receptor domain–containing adaptor inducing IFN-ß–, IFN promoter-stimulator 1–, and inhibitor of {kappa}B kinase–independent, thus excluding all known TLRs and cytosolic helicase receptors. DMXAA pretreatment of mouse macrophages induced a state of tolerance to LPS and vice versa. In contrast to LPS stimulation, DMXAA-induced IRF-3 dimerization and IFN-ß expression were inhibited by salicylic acid. These findings detail a novel pathway for TBK1-mediated IRF-3 activation and provide new insights into the mechanism of this new class of chemotherapeutic drugs.

Abbreviations used: DMXAA, 5,6-dimethylxanthenone-4-acetic acid; GST, glutathione S transferase; I{kappa}B, inhibitor of {kappa}B; IKK, I{kappa}B kinase; IP-10, IFN-inducible protein 10; IPS-1, IFN-ß promoter-stimulator 1; IRF-3, IFN regulatory factor 3; MAPK, mitogen-activated protein kinase; MEF, mouse embryonic fibroblast; MyD88, myeloid differentiation factor 88; PAMP, pathogen-associated molecular pattern; PRD, positive regulatory domain; RANTES, regulated on activation, normal T expressed and secreted; RIG-I, retinoic acid–inducible gene I; SA, salicylic acid; TBK1, TANK-binding kinase 1; TIR, Toll–IL-1 resistance; TLR, Toll-like receptor; TRAM, TRIF-related adaptor molecule; TRIF, TIR domain–containing adaptor inducing IFN-ß; VDA, vascular disrupting agent.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

Related Article

Antitumor drug sends new signals
Hema Bashyam
J. Exp. Med. 2007 204: 1505b. [Full Text] [PDF]



This article has been cited by other articles:



  Home | Help | Feedback | Subscriptions | Archive | Search
TABLE OF CONTENTS